140 related articles for article (PubMed ID: 36109330)
1. Comparing Rates of Polycythemia in Hypogonadal Men Using Nasal Testosterone Gel Versus Intramuscular Testosterone: Update of a Randomized Clinical Trial.
Ory J; Diaz P; Rivero MJ; Clavijo RI; Thirumavalavan N; Blachman-Braun R; Loloi J; Bernstein A; Ramasamy R
Eur Urol Focus; 2023 Jan; 9(1):14-16. PubMed ID: 36109330
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Hematocrit Change in Testosterone-deficient Men Treated With Intranasal Testosterone Gel vs Intramuscular Testosterone Cypionate: A Randomized Clinical Trial.
Rivero MJ; Ory J; Diaz P; Thirumavalavan N; Han S; Reis IM; Ramasamy R
J Urol; 2023 Jul; 210(1):162-170. PubMed ID: 37126399
[TBL] [Abstract][Full Text] [Related]
3. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy.
Ory J; Nackeeran S; Balaji NC; Hare JM; Ramasamy AR
J Urol; 2022 Jun; 207(6):1295-1301. PubMed ID: 35050717
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Secondary Polycythemia in Hypogonadal Men Treated with Clomiphene Citrate versus Testosterone Replacement: A Multi-Institutional Study.
Wheeler KM; Smith RP; Kumar RA; Setia S; Costabile RA; Kavoussi PK
J Urol; 2017 Apr; 197(4):1127-1131. PubMed ID: 27984109
[TBL] [Abstract][Full Text] [Related]
5. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets.
Ip FF; di Pierro I; Brown R; Cunningham I; Handelsman DJ; Liu PY
Eur J Endocrinol; 2010 Feb; 162(2):385-90. PubMed ID: 19903801
[TBL] [Abstract][Full Text] [Related]
6. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
Lundy SD; Parekh NV; Shoskes DA
J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
[TBL] [Abstract][Full Text] [Related]
7. Testosterone replacement therapy and polycythemia in HIV-infected patients.
Vorkas CK; Vaamonde CM; Glesby MJ
AIDS; 2012 Jan; 26(2):243-5. PubMed ID: 22008652
[TBL] [Abstract][Full Text] [Related]
8. Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia.
Rotker KL; Alavian M; Nelson B; Baird GL; Miner MM; Sigman M; Hwang K
Asian J Androl; 2018; 20(2):195-199. PubMed ID: 29205178
[TBL] [Abstract][Full Text] [Related]
9. Hematocrit Response and Risk Factors for Significant Hematocrit Elevation with Implantable Testosterone Pellets.
Hayden RP; Bennett NE; Tanrikut C
J Urol; 2016 Dec; 196(6):1715-1720. PubMed ID: 27287525
[TBL] [Abstract][Full Text] [Related]
10. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. Letter.
Kaplan-Marans E
J Urol; 2022 Sep; 208(3):566-567. PubMed ID: 35648648
[No Abstract] [Full Text] [Related]
11. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. Reply.
Ory J; Ramasamy R
J Urol; 2022 Sep; 208(3):567. PubMed ID: 35648647
[No Abstract] [Full Text] [Related]
12. [Andrological testosterone replacement therapy].
Paasch U; Glander HJ; Stolzenburg JU
Urologe A; 2009 Jan; 48(1):79-86; quiz 87. PubMed ID: 19156339
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis.
Hajjar RR; Kaiser FE; Morley JE
J Clin Endocrinol Metab; 1997 Nov; 82(11):3793-6. PubMed ID: 9360543
[TBL] [Abstract][Full Text] [Related]
14. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study.
Li H; Mitchell L; Zhang X; Heiselman D; Motsko S
J Sex Med; 2017 Nov; 14(11):1307-1317. PubMed ID: 29110802
[TBL] [Abstract][Full Text] [Related]
15. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
Rogol AD; Tkachenko N; Bryson N
Andrology; 2016 Jan; 4(1):46-54. PubMed ID: 26695758
[TBL] [Abstract][Full Text] [Related]
16. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
Zitzmann M; Cremers JF; Krallmann C; Kliesch S
Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
[TBL] [Abstract][Full Text] [Related]
17. Testosterone nasal gel (Natesto) for hypogonadism.
Med Lett Drugs Ther; 2015 May; 57(1468):73-4. PubMed ID: 25941957
[TBL] [Abstract][Full Text] [Related]
18. [Abdominal pain and hypertension in a 55-year-old male patient].
Kofler T; Yueksel F; Dirnhofer S; Donath MY; Trendelenburg M
Internist (Berl); 2017 Apr; 58(4):397-401. PubMed ID: 28005140
[TBL] [Abstract][Full Text] [Related]
19. A cross-sectional comparison of secondary polycythemia in testosterone-deficient men treated with nasal testosterone gel vs. intramuscular testosterone cypionate.
Best JC; Gonzalez D; Masterson TA; Blachman-Braun R; Pai R; Ramasamy R
Can Urol Assoc J; 2021 Feb; 15(2):E118-E122. PubMed ID: 32744998
[TBL] [Abstract][Full Text] [Related]
20. Testosterone deficiency syndrome: benefits, risks, and realities associated with testosterone replacement therapy.
Hassan J; Barkin J
Can J Urol; 2016 Feb; 23(Suppl 1):20-30. PubMed ID: 26924592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
